Healthcare investment firm Vivo Capital leads $55m round in Beijing Innocare

Healthcare investment firm Vivo Capital leads $55m round in Beijing Innocare

Healthcare investment firm Vivo Capital has led the $55-million funding round of Beijing Innocare, a biopharmaceutical company that develops treatment for cancer and autoimmune diseases, with CCB Capital also backing the round.

Bring stories like this into your inbox every day.

Sign up for our newsletter - The Daily Brief
Subscribe to Newsletter